MDS patients with TP53 mutation respond equally to hypomethylating agents (HMA) but has significantly shorter response duration compared to patients with wild type TP53
Titel:
MDS patients with TP53 mutation respond equally to hypomethylating agents (HMA) but has significantly shorter response duration compared to patients with wild type TP53
Auteur:
Takahashi, Koichi Kantarjian, Hagop Patel, Keyur Bueso-Ramos, Carlos Kadia, Tapan Jabbour, Elias DiNardo, Courtney Estrov, Zeev Daver, Naval Konopleva, Marina Pierce, Sherry Cortes, Jorge Futreal, Andrew Garcia-Manero, Guillermo